Phases précoces tumeurs solides XL 184_021 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Paris
Appareil pulmonaire AMG20190294 A Non-interventional Biomarker Study on the;Molecular Evaluation of Archival Tumor Tissue in;Subjects with Non-Small Cell Lung Cancer;(NSCLC) Paris NICOLAS GIRARD
Appareil pulmonaire GeoMETry-III (CINC280A2301) A phase III, randomized, controlled, open-label, multicenter,;global study of capmatinib versus SoC docetaxel;chemotherapy in previously treated patients with EGFR wt,;ALK negative, locally advanced or metastatic (stage IIIB/IIIC;or IV) NSCLC harboring MET exon 14 skipping mutation;(METÀex14) Paris CATHERINE DANIEL
Sein métastatique HER2+ HER2CLIMB02 (SGNTUC-016) A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer Paris
Phases précoces tumeurs solides INCB 86550-102 A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors Paris CHRISTOPHE LE TOURNEAU
Appareil pulmonaire MS200647-0005 A Multicenter, Double Blind, Randomized,Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer· Protocol MS200647-0005 Paris CATHERINE DANIEL
VADS TrilynX (Debio 1143-SCCHN-301) A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in;combination with platinum-based chemotherapy and standard fractionation intensitymodulated;radiotherapy in patients with locally advanced squamous cell carcinoma of;the head and neck, suitable for definitive chemoradiotherapy (TrilynX). Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ DESTINY-Breast06 (D9670C00001) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator·s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) Paris, Saint-Cloud JEAN-YVES PIERGA, ETIENNE BRAIN
Appareil pulmonaire AMG 20190009_25004 A Phase 3 Multicenter, Randomized, Open;Label, Active-controlled, Study of AMG 510;Versus Docetaxel for the Treatment of Previously;Treated Locally Advanced and Unresectable or;Metastatic NSCLC Subjects With Mutated;KRAS p.G12C Paris NICOLAS GIRARD
VADS M19-894 A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability,;Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy;Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Paris CHRISTOPHE LE TOURNEAU